These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 16652143)
41. Expression of clusterin, XIAP and survivin, and their changes by camptothecin (CPT) treatment in CPT-resistant PC-3 and CPT-sensitive LNCaP cells. Mizutani K; Matsumoto K; Hasegawa N; Deguchi T; Nozawa Y Exp Oncol; 2006 Sep; 28(3):209-15. PubMed ID: 17080014 [TBL] [Abstract][Full Text] [Related]
42. Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells. Kominsky SL; Hobeika AC; Lake FA; Torres BA; Johnson HM Cancer Res; 2000 Jul; 60(14):3904-8. PubMed ID: 10919667 [TBL] [Abstract][Full Text] [Related]
43. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Zerbini LF; Wang Y; Cho JY; Libermann TA Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841 [TBL] [Abstract][Full Text] [Related]
44. The role of clusterin in prostate cancer: treatment resistance and potential as a therapeutic target. Muhammad LA; Saad F Expert Rev Anticancer Ther; 2015; 15(9):1049-61. PubMed ID: 26313417 [TBL] [Abstract][Full Text] [Related]
45. Clusterin and chemoresistance. Djeu JY; Wei S Adv Cancer Res; 2009; 105():77-92. PubMed ID: 19879424 [TBL] [Abstract][Full Text] [Related]
46. Proteotranscriptomic Measurements of E6-Associated Protein (E6AP) Targets in DU145 Prostate Cancer Cells. Gulati T; Huang C; Caramia F; Raghu D; Paul PJ; Goode RJA; Keam SP; Williams SG; Haupt S; Kleifeld O; Schittenhelm RB; Gamell C; Haupt Y Mol Cell Proteomics; 2018 Jun; 17(6):1170-1183. PubMed ID: 29463595 [TBL] [Abstract][Full Text] [Related]
47. RNA sequencing reveals upregulation of a transcriptomic program associated with stemness in metastatic prostate cancer cells selected for taxane resistance. Cajigas-Du Ross CK; Martinez SR; Woods-Burnham L; Durán AM; Roy S; Basu A; Ramirez JA; Ortiz-Hernández GL; Ríos-Colón L; Chirshev E; Sanchez-Hernandez ES; Soto U; Greco C; Boucheix C; Chen X; Unternaehrer J; Wang C; Casiano CA Oncotarget; 2018 Jul; 9(54):30363-30384. PubMed ID: 30100995 [TBL] [Abstract][Full Text] [Related]
48. Expression profile-based screening for critical genes reveals S100A4, ACKR3 and CDH1 in docetaxel-resistant prostate cancer cells. Zhu S; Min Z; Qiao X; Chen S; Yang J; Zhang X; Liu X; Ran W; Lv R; Lin Y; Wang J Aging (Albany NY); 2019 Dec; 11(24):12754-12772. PubMed ID: 31895690 [TBL] [Abstract][Full Text] [Related]
49. Prostate Tumor Overexpressed-1 (PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cells. Cánovas V; Puñal Y; Maggio V; Redondo E; Marín M; Mellado B; Olivan M; Lleonart M; Planas J; Morote J; Paciucci R Oncotarget; 2017 Aug; 8(35):59165-59180. PubMed ID: 28938627 [TBL] [Abstract][Full Text] [Related]
50. CNTN-1 promotes docetaxel resistance and epithelial-to-mesenchymal transition via the PI3K/Akt signaling pathway in prostate cancer. Chen B; Zhang Y; Li C; Xu P; Gao Y; Xu Y Arch Med Sci; 2021; 17(1):152-165. PubMed ID: 33488868 [TBL] [Abstract][Full Text] [Related]
51. Identification of mutations, gene expression changes and fusion transcripts by whole transcriptome RNAseq in docetaxel resistant prostate cancer cells. Ma Y; Miao Y; Peng Z; Sandgren J; De Ståhl TD; Huss M; Lennartsson L; Liu Y; Nistér M; Nilsson S; Li C Springerplus; 2016; 5(1):1861. PubMed ID: 27822437 [TBL] [Abstract][Full Text] [Related]
52. CD44 Wróbel T; Luty M; Catapano J; Karnas E; Szczygieł M; Piwowarczyk K; Ryszawy D; Drabik G; Zuba-Surma E; Siedlar M; Madeja Z; Elas M; Czyż J Stem Cells; 2020 Sep; 38(12):1544-56. PubMed ID: 32985018 [TBL] [Abstract][Full Text] [Related]
53. Microtubule-associated protein tau is associated with the resistance to docetaxel in prostate cancer cell lines. Yang J; Yu Y; Liu W; Li Z; Wei Z; Jiang R Res Rep Urol; 2017; 9():71-77. PubMed ID: 28507979 [TBL] [Abstract][Full Text] [Related]
54. Detecting soluble clusterin in in-vitro and in-vivo models of prostate cancer. Girard FP; Byrne J; Downes M; Fanning D; Desgrandchamps F; Fitzpatrick JM; Watson RW Neoplasma; 2010; 57(5):488-93. PubMed ID: 20568904 [TBL] [Abstract][Full Text] [Related]
56. Clusterin: a key player in cancer chemoresistance and its inhibition. Koltai T Onco Targets Ther; 2014; 7():447-56. PubMed ID: 24672247 [TBL] [Abstract][Full Text] [Related]
57. Phenotype plasticity and altered sensitivity to chemotherapeutic agents in aggressive prostate cancer cells. Paxson AI; Chang LH; Gard JMC; Harryman WL; Nelson CS; Salmon SB; Marr KD; Wachsmuth LM; Ramanathan A; Ran J; Kapoor A; Marugan JJ; Henderson MJ; Sanchez TW; Cress AE Front Cell Dev Biol; 2023; 11():1285372. PubMed ID: 38046670 [TBL] [Abstract][Full Text] [Related]